Non-receptor tyrosine kinase
|non-membrane spanning protein tyrosine kinase|
|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / EGO|
Non-receptor tyrosine kinases (nRTKs) are cytoplasmic enzymes that are responsible for catalysing the transfer of a phosphate group from a nucleoside triphosphate donor, such as ATP, to a tyrosine residues in proteins. Non-receptor tyrosine kinases are a subgroup of protein family tyrosine kinases, enzymes that can transfer the phosphate group from ATP to a tyrosine residue of a protein (phosphorylation). These enzymes regulate many cellular functions by switching on or switching off other enzymes in a cell.
Unlike the receptor tyrosine kinases (RTKs), the second subgroup of tyrosine kinases, the non-receptor tyrosine kinases are cytoplasmic enzymes. Thirty-two non-receptor tyrosine kinases have been identified in human cells (EC 126.96.36.199). Non-receptor tyrosine kinases regulate for example cell's growth, proliferation, differentiation, adhesion, migration and apoptosis and they are critical components in the regulation of the immune system.
The main function of nRTKs is their involvement in signal transduction in activated T- and B-cells in the immune system; signaling by many receptors is dependent on nRTKs including T-cell receptors (TCR); B-cell receptors (BCR), IL-2 receptors (IL-2R), Ig receptors, erythropoietin (EpoR) and prolactin receptors. CD4 and CD8 receptors on T lymphocytes require for their signaling the Src family member Lck. When antigen binds to T-cell receptor, Lck becomes autophosphorylated and phosphorylates the zeta chain of the T-cell receptor, subsequently another nRTK, Zap70, binds to this T-cell receptor and then participates in downstream signaling events that mediate transcriptional activation of cytokine genes. Another Src family member Lyn is involved in signaling mediated by B-cell receptor. Lyn is activated by stimulation of B-cell receptor, which leads to the recruitment and phosphorylation of Zap70-related nRTK, Syk. Another nRTK, Btk, is also involved in signaling mediated by the B-cell receptor. Mutations in the Btk gene are responsible for X-linked agammaglobulinemia, a disease characterized by the lack of mature B-cells.
Unlike receptor tyrosine kinases, nRTKs lack receptor-like features such as an extracellular ligand-binding domain and a transmembrane-spanning region. The most of nRTKs are localized in the cytoplasm, but some nRTKs are anchored to the cell membrane through amino-terminal modification. These enzymes commonly have a modular construction and individual domains are joined together by linker sequences. One of the important domain of nRTKs is tyrosine kinase catalytic domain, which is about 275 residues in length. The structure of catalytic domain can be divided to small and large lobe, ATP binds to a small lobe and protein substrate binds to a large lobe. Upon binding of ATP and substrate to nRTKs, catalysis of phosphate transfer occurs in a cleft between these two lobes. It was found that nRTKs have some sequence preference around the target Tyr. For example, Src preferred sequence is Glu–Glu/Asp–Ile–Tyr–Gly/Glu–Glu–Phe and Abl preferred sequence is Ile/Val–Tyr–Gly–Val–Leu/Val. Different preferred sequences around Tyr in Src and Abl suggest that these two types of nRTKs phosphorylates different targets. Non-receptor tyrosine kinases do not contain only a tyrosine kinase domain, nRTKs possess also domains that mediate protein-protein, protein-lipid, and protein-DNA interactions. One of the protein-protein interaction domains in nRTKs are the Src homology 2 (SH2) and 3 (SH3) domains. The longer SH2 domain (~100 residues) binds phosphotyrosine (P-Tyr) residues in a sequence-specific manner. The P-Tyr interacts with SH domain in a deep cleft, which cannot bind unphosphorylated Tyr. The SH3 domain is smaller (~60 residues) and binds proline-containing sequences capable of forming a polyproline type II helix. Some NRTKs without SH2 and SH3 domains possess some subfamily-specific domains used for protein-protein interactions. For example specific domains that target enzymes to the cytoplasmic part of cytokine receptors (Jak family) or two domains: an integrin-binding domain and a focal adhesion-binding domain (Fak family). The nRTK Abl possess the SH2 and SH3 domains, but also possesses other domains for interactions: F actin–binding domain and a DNA-binding domain contains a nuclear localization signal and is found in both the nucleus and the cytoplasm. In addition to SH2 and SH3 domains, Btk/Tec subfamily of nRTKs possess another modular domain, a pleckstrin homology (PH) domain. These PH domains bind to phosphatidylinositol lipids that have been phosphorylated at particular positions on the head group. These enzymes can bind to activated signaling complexes at the membrane through PH domain interactions with phosphorylated phosphatidylinositol lipids.
The most common theme in nRTKs and RTK regulation is tyrosine phosphorylation. With few exceptions, phosphorylation of tyrosines in the activation loop of nRTKs leads to an increase in enzymatic activity. Activation loop phosphorylation occurs via trans-autophosphorylation or phosphorylation by a different nRTKs. It is possible to negatively regulate kinase activity by phosphorylation of tyrosines outside of the activation loop. Protein tyrosine phoshatases (PTPs) restore nRTKs to their basal state of activity. In some cases PTPs positively regulate nRTKs activity.
Src and Abl
Tyrosine kinases of Src family contain the same typical structure: myristoylated terminus, a region of positively charged residues, a short region with low sequence homology, SH3 and SH2 domains, a tyrosine kinase domain, and a short carboxy-terminal tail. There are two important regulatory tyrosine phosphorylation sites. To repress kinase activity it is possible by phosphorylation of Tyr-527 in the carboxy-terminal tail of Src by the NRTK Csk. By the experiment of v-Src, an oncogenic variant of Src, the importance of this phosphorylation site was confirmed. This oncogenic v-Src is a product of the Rous sarcoma virus and as a result of an carboxy-terminal truncation, v-Src lacks the negative regulatory site Tyr-527 leading this enzyme to be constitutively active that in turn causes uncontrolled growth of infected cells. Moreover, substitution of this tyrosine with phenylalanine in c-Src results in activation. A second regulatory phosphorylation site in Src is Tyr-416. This is an autophosphorylation site in the activation loop. It was found that a phosphorylation of Tyr-416 and Tyr-416 can suppressing the transforming ability of the activating Tyr-527→Phe mutation by Tyr-416→Phe mutation leads to maximal stimulation of kinase activity.
Both the SH2 and SH3 domains are important for a negative regulation of Src activity. Mutations in the SH2 and SH3 domains that disrupt binding of phosphotyrosine lead to activation of kinase activity. Although the nRTK Abl contains SH3, SH2, and kinase domains in the same linear order as in Src, regulation of Abl is different. Abl lacks the negative regulatory phosphorylation site that is present in the carboxy terminus of Src, so the carboxy terminus of Abl does not have a functional role in the control of kinase activity. In a contrast to Src, mutations in the SH2 domain of Abl that abrogates phosphotyrosine binding do not activate Abl in vivo. For the repression of kinase activity of Abl is important the SH3 domain; mutations in the SH3 domain result in activation of Abl and cellular transformation.
ZAP70/Syk and JAKs
The kinase activity of Syk is regulated by the SH2 domains. Binding of the two SH2 domains to the tyrosine-phosphorylated ITAM (immunoreceptor tyrosine-based activation motif) sequences in the ζ chain of the T-cell receptor is thought to relieve an inhibitory restraint on the kinase domain, leading to stimulation of catalytic activity. Kinase activity of Zap70 can be increased by phosphorylation of Tyr-493 in the activation loop by Src family member Lck. Conversely the phosphorylation of Tyr-492 inhibit the kinase activity of Zap70; the mutation of Tyr-492 to phenylalanine results in Zap70 hyperactivity.
Jak family members possess a fully functional tyrosine kinase domain and additionally pseudo-kinase domain in which substitution of several key catalytic residues leads to inactivation of kinase activity. This pseudo-kinase domain is enzymatically nonfunctional, but maybe it plays a role in the regulation of Jak activity. The experiments with a mutant of the Jak family member Tyk2, in which the pseudo-kinase domain is deleted, showed that these mutant enzyme lacks catalytic activity in vitro and is not capable of interferon-mediated signal transduction. In contrast, another mutant of the Jak family Jak2, also lacking the pseudo-kinase domain, was able to mediate growth hormone signaling. The role of the pseudo-kinase domain in Jak regulation is still not fully understood. There are two tyrosine phosphorylation sites within the activation loop. It is known that the autophosphorylation of the first of these tyrosines is important for stimulation of tyrosine kinase activity and biological function, but the role of the second tyrosine is not clear.
JAKs are also regulated by SOCS (suppressor of cytokine signaling) proteins. These proteins contain a pseudo-substrate sequence thought to interfere with Jak substrate binding and phosphoryl transfer. In addition to a pseudo-substrate sequence,SOCS proteins possess an SH2 domain that binds to a phosphotyrosine in the Jak activation loop, which may facilitate interaction between the pseudosubstrate sequence and the kinase domain. Binding of the SH2 domain to the activation loop could also block substrate access directly or alter the conformation of the activation loop to repress catalytic activity.
The mutation in a gene for non-receptor tyrosine kinase can results an aberrant activity of this enzyme. This pathologically increased activity of nRTK may be responsible for growth and progression of cancer cells, the induction of drug-resistance, formation of metastasis and tumor neovascularization. The inhibition of nRTKs could help to a treatment of these tumors. Some of nRTKs inhibitors are already tested as an anti-cancer agents. This targed therapy blocks intracellular processes involved in the tumor transformation of cells and / or maintenance of malignant phenotype of tumor cells. For the targeted blocade of RTK are usually used a monoclonal antibodies, which block extracellular domain of the receptor and prevent the binding of a ligand. For the specific blocade of nRTKs, however, are used low molecular weight substances called tyrosine-kinase inhibitors (TKI), that block the transduction cascade either at the intracytosplasmatic level, or directly block the nRTKs.
Examples of non-receptor tyrosine kinases include:
- Weiss A, Littman DR (January 1994). "Signal transduction by lymphocyte antigen receptors". Cell 76 (2): 263–74. doi:10.1016/0092-8674(94)90334-4. PMID 8293463.
- Vihinen M, Vetrie D, Maniar HS, Ochs HD, Zhu Q, Vorechovský I, Webster AD, Notarangelo LD, Nilsson L, Sowadski JM (December 1994). "Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease". Proc. Natl. Acad. Sci. U.S.A. 91 (26): 12803–7. Bibcode:1994PNAS...9112803V. doi:10.1073/pnas.91.26.12803. PMC 45528. PMID 7809124.
- Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S (January 1993). "Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia". Cell 72 (2): 279–90. doi:10.1016/0092-8674(93)90667-F. PMID 8425221.
- Neet K, Hunter T (February 1996). "Vertebrate non-receptor protein-tyrosine kinase families". Genes Cells 1 (2): 147–69. doi:10.1046/j.1365-2443.1996.d01-234.x. PMID 9140060.
- Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C (February 1995). "Catalytic specificity of protein-tyrosine kinases is critical for selective signalling". Nature 373 (6514): 536–9. Bibcode:1995Natur.373..536S. doi:10.1038/373536a0. PMID 7845468.
- Kuriyan J, Cowburn D (1997). "Modular peptide recognition domains in eukaryotic signaling". Annu Rev Biophys Biomol Struct 26: 259–88. doi:10.1146/annurev.biophys.26.1.259. PMID 9241420.
- Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, Lemmon MA, Aronheim A, Skolnik EY (September 1998). "Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast". EMBO J. 17 (18): 5374–87. doi:10.1093/emboj/17.18.5374. PMC 1170863. PMID 9736615.
- Tonks NK, Neel BG (November 1996). "From form to function: signaling by protein tyrosine phosphatases". Cell 87 (3): 365–8. doi:10.1016/S0092-8674(00)81357-4. PMID 8898190.
- Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H (May 1991). "Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src". Nature 351 (6321): 69–72. Bibcode:1991Natur.351...69N. doi:10.1038/351069a0. PMID 1709258.
- Cooper JA, Gould KL, Cartwright CA, Hunter T (March 1986). "Tyr527 is phosphorylated in pp60c-src: implications for regulation". Science 231 (4744): 1431–4. Bibcode:1986Sci...231.1431C. doi:10.1126/science.2420005. PMID 2420005.
- Kmiecik TE, Shalloway D (April 1987). "Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation". Cell 49 (1): 65–73. doi:10.1016/0092-8674(87)90756-2. PMID 3103925.
- Erpel T, Superti-Furga G, Courtneidge SA (March 1995). "Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions". EMBO J. 14 (5): 963–75. PMC 398168. PMID 7534229.
- Mayer BJ, Baltimore D (May 1994). "Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase". Mol. Cell. Biol. 14 (5): 2883–94. PMC 358656. PMID 8164650.
- Van Etten RA, Debnath J, Zhou H, Casasnovas JM (May 1995). "Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro". Oncogene 10 (10): 1977–88. PMID 7539119.
- Shiue L, Zoller MJ, Brugge JS (May 1995). "Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE". J. Biol. Chem. 270 (18): 10498–502. doi:10.1074/jbc.270.18.10498. PMID 7537732.
- Kong G, Dalton M, Bubeck Wardenburg J, Straus D, Kurosaki T, Chan AC (September 1996). "Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function". Mol. Cell. Biol. 16 (9): 5026–35. PMC 231504. PMID 8756661.
- Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zürcher G, Ziemiecki A (April 1991). "Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase". Mol. Cell. Biol. 11 (4): 2057–65. PMC 359893. PMID 1848670.
- Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uzé G, Pellegrini S (February 1995). "Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction". J. Biol. Chem. 270 (7): 3327–34. doi:10.1074/jbc.270.7.3327. PMID 7531704.
- Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN (May 1997). "Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop". Mol. Cell. Biol. 17 (5): 2497–501. PMC 232098. PMID 9111318.
- Starr R, Novak U, Willson TA, Inglese M, Murphy V, Alexander WS, Metcalf D, Nicola NA, Hilton DJ, Ernst M (August 1997). "Distinct roles for leukemia inhibitory factor receptor alpha-chain and gp130 in cell type-specific signal transduction". J. Biol. Chem. 272 (32): 19982–6. doi:10.1074/jbc.272.32.19982. PMID 9242667.
- Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A (June 1999). "Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain". Genes Cells 4 (6): 339–51. doi:10.1046/j.1365-2443.1999.00263.x. PMID 10421843.